MilliporeSigma Capacity Update June 2023: Biologics

Getting your clinical or commercial drug substance supply fast is crucial to reach clinical phases and ultimately, the market. Our Millipore® CTDMO services portfolio includes contract development and manufacturing in Martillac, France; Burlington, MA, US; and Shanghai, China, and global contract testing services.

Our Martillac site was established in 1987 and has grown into one of MilliporeSigma’s fully integrated site for mAbs & r-proteins. Leveraging flexible single-use technology and accelerated tech transfer, the site features capacity and expertise from pre-clinical development to GMP clinical and commercial manufacturing, alongside dedicated QC labs.

In this presentation from the June 2023 Outsourced Pharma Capacity Update, join us to explore our full capabilities and see our site with a focus on our recently opened, state-of-the-art 2,700m-facility for global commercial drug substance supply at 200L and 2,000L scales.

In this session you’ll:

• Hear about the capabilities to accelerate time to clinic and market
• Learn about the importance of efficient tech transfer
• See our commercial facility design and flexible capacity